

Good stewardship of medications and how it effects quality







Medications can alter all 4 M's of Age-Friendly care

- What Matters
- Medication
- Mentation (Mind & Mood)
- Mobility



Medications can impact a resident's functional status and quality of life.

Insomnia

Mobility

Appetite

Delirium

Common Medication Side-effects **Adverse Drug Events**

Inactivity

Social Withdrawal

Depression

Decline in ADLs

Falls


Pressure Ulcers

Weight loss

Behaviors

Effects to

Quality





Medication side effects



Manifestations of medication side-effects

- Poor Sleep
- Comfort
- Cognition
- Unstable Balance
- Appetite

Interventions

- Timeline and Root Cause Analysis
- Fewer Meds equals fewer side effects
- Gradual Dose Reduction


Use of Tools

- Comprehensive Assessment Tool
- History
- Education and Communication Staff and Family
- Narcan for Opioid Adverse Drug Events
- Tapering Tools
- Agreements with Resident and Families





For the First Time in U.S. History Older Adults Are Projected to Outnumber Children by 2034




73.6 77.0 76.5 80.1 49.2 2016 '20 '25 '30 2034 '40 '45 '50 '55 2060 Note: 2016 data are estimates not projections.



(millions)

U.S. Department of Commerce U.S. CENSUS BUREAU census.gov Source: National Population Projections, 2017 www.census.gov/programs-surveys /popproj.html





Performance Improvement



| ☐ Falls ☐ Effect on Function- ADLs ☐ Behaviors effecting others |
|-----------------------------------------------------------------|
| Interview: |
| ☐ Appetite |
| Cognition |
| ■ Nausea |
| ☐ Dizziness |
| ☐ Intended Resolution |
| Condition Evaluation |

Performance Improvement Project (PIP) Documentation

Nursing Home: Comfort Home Start Date: _____

PIP Team Members:

| Staff Name | Title | |
|------------|------------------|--|
| | Medical Director | |
| | DON | |
| | Pharmacy | |
| | MDS Nurse | |
| | | |

PIP Team Project:

| Quality Measure of Focus | Baseline Rate of QM | Improvement Goal for QM | Goal Rate | Date to reach the goal rate |
|--------------------------|------------------------|-------------------------|-----------|--------------------------------|
| Antipsychotic Meds | 20.1% | Below State Average | 10% | Dec 2021 |

Goal Monitoring:

| Current Date | Current Rate | Current Date | Current Rate | Current Date | Current Rate |
|--------------|--------------|--------------|--------------|--------------|--------------|
| Nov 2022 | 16.1% | | | | |
| Dec 2022 | 18.2% | | | | |
| Jan 2023 | 18.8% | | | | |
| Feb 2023 | 13.3% | | | | |
| Mar 2023 | 12.9% | | | | |
| | | | | | |
| | | | | | |

Interventions: The following are the interventions Implemented:

| Start Date | Intervention Description | Intervention Notes | Outcome/Results |
|------------|--------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|-----------------------------|
| Nov 2022 | Reviewing Antipsychotic Meds rate and Residents triggered on MDS Report- | Identify current resident list and if candidate for <u>GDR</u> ; current rate below the state average | Continue to monitor monthly |
| Dec 2022 | PIP team reviewing new admissions for use of Antipsychotic Meds | Identify residents early to determine if candidate for GDR | |
| Dec 2022 | Monitor Timeline of Events for individual residents | Correlate multiple quality concerns | |
| | | | |
| | | | |
| | | | |







Informed Medication Consent



PSYCHOACTIVE MEDICATION THERAPY INFORMED CONSENT FORM

Use a separate form for each medication.

| | | and the amount of | day and the second of the second | a fee a blakes been to the | december 5.5 | |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------|--|
| necessary to use psychoa action or for the convenie | active medical intervent | tions under certain | d to promote our resident conditions. Medication inte | | | |
| Psychoactive medication | prescribed for resider | ıt | | | | |
| is | | | agnosis of | | | |
| The specific condition(s) Adjustment D Agitation Anxiety Bipolar Dison Catatonia Combative B: Improved Fur Reduced Adv | Disorder D D D D D D D D D D D D D D D D D D D | s): ementia w/Psycho elusions epression ritability bsessive Compuls anic vention include(s): | tic Behavior | aranoia chizophrenia exual Disorder deeping Disorder deeping Disorder deeping Disorder ther | 7 | |
| Antipsychotic | Anti-Anxiety | Hypnotic | Antidepressant | Anti-Manic | Psychomotor Stimulant | |
| Blurred Vision Confusion Constipation Drooling Dry Mouth Involuntary Movements Muscle Rigidity Restlessness Sedation Sleep Disturbances Stiffness of the Neck | Appetite Changes Blurred Vision Confusion Dizziness Drowsiness Fatigue Hypotension Nighmares Sedation Slurred Speech Urinary Retention Dry Mouth | Anxiety Confusion Dizziness Fatigue Hallucinations Headache Lightheadednes Mania Nightmares Sedation Syncope | Appetite Changes Blurred Vision Constipation Dry Mouth Dyspepsia Headache Hypotension Insomnia Weight Changes Urinary Retention | Bradycardia Confusion Drowsiness Hypotension Impaired Cognition Impaired Vision Nausea Nephritic Syndrome Seizures Tremors | Anorexia Dry Mouth Impaired Taste Insomnia Nervousness | |
| ☐ I GIVE my full consent the usage of the medi | 13 months □ 6 mon nt for the use of the ma ication should be gradu onsent for the use of th | nths 12 mont edication indicated ually decreased to ne medication indica- | hs Prolonged treatm above. I understand that the lowest possible dosag- cated above. I realize the othe nursing staff to approp | once the targeted beha ge and frequency. dangers of not taking th | | |
| Signature of Resident | | | | Date | | |
| Signature of Representative | | | | Date | | |
| Signature of Representative | | | | | | |
| Signature of Representative | | | | Date | | |
| , | ing Consent | | | Date | | |

Form 3684/2P Rev. 1209 @ 1997 IRRCZZ, Des Moines, IA (800) 247-2340 Desembarios complete or una violates complete law, www.DisenCom.com, prayana a u

BRIGGSHealthcare

PSYCHOACTIVE MEDICATION THERAPY INFORMED CONSENT FORM





Creating an Environment and Sustainable Culture

Supporting Actions

- Develop role descriptions to facilitate collaboration amongst the health care team
- Create dedicated time and space for discussions during each shift, at care conferences and as needed
- *3. Establish a monitoring and evaluation framework for the impact of health care provider and personnel collaborations on deprescribing, care plans, quality of life, retention and workload
- *4. Recognize health care providers and personnel who identify signs and symptoms that lead to a deprescribing conversation

All members of the health care team will participate in conversations about deprescribing.

People living in LTC homes and their families/caregivers will participate in shared decision making to establish and monitor goals of care with respect to medication use considering effectiveness, safety and non-drug alternatives.

Supporting Actions

- *1. Use approaches like modelling to illustrate positive outcomes through personal story sharing
- * 2. Offer/develop educational resources for people living in LTC homes and their family/caregivers to inform them about their opportunities for contributions and to standardize approaches
- *3. Schedule timely medication-focused discussions with the people living in LTC homes, families, caregivers and the health care team
- Develop regulations that mandate and monitor the person/family/caregiver involvement in care planning and medication review

Supporting Actions

- * 1. Provide education and training using tools that link signs and symptoms to medication-related effects
- Use approaches like modelling to promote health care provider and personnel engagement through personal story sharing
- 3. Make tools to help monitor changes in signs and symptoms accessible at the point-of-care

All health care providers and personnel will observe for signs and symptoms in the people they care for, reporting changes as a result of medication adjustments, or changes that might prompt review for deprescribing.

Prescribers in every health care setting will document reasons for use, goals and timelines for each medication.

Supporting Actions

- *1. Incorporate relevant components (reason for use, goals of therapy, planned duration of use and date for review) into e-prescribing and electronic health records
- Develop regulations that mandate and monitor associated documentation standards and compliance
- 3. Enable medication information sharing via centralized electronic records

• Science Direct.com https://ars.els-cdn.com/content/image/1-s2.0-S2667276622000671-gr2_lrg.jpg



^{*} Asterisks represent prioritized actions

Story Board-Medication Culture Change





• Suggestions for Medication Stewardship.







Dawn Jelinek Age-Friendly Clinics and LTC

OFMQ- GWEP- OkDCN
Senior Clinical Consultant

djelinek@ofmq.com

405-651-4796







